BHC
Bausch Health Companies Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
Momentum inputs (comparable managers):
holder breadth +8.3% ·
share flow -14.1% ·
net new positions +7.7%
— formula
Ownership fragmentation — more holders, smaller aggregate stake
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 80 | -5 | 75.64M | $382.99M | +3 | −7 |
| Q1 2026 | 85 | -6 | 79.75M | $438.97M | +2 | −9 |
| Q4 2025 | 92 | +1 | 89.74M | $627.51M | +2 | — |
| Q3 2025 | 19 | +1 | 25.30M | $166.30M | +2 | −2 |
| Q2 2025 | 16 | -1 | 54.52M | $364.89M | — | −1 |
| Q1 2025 | 15 | +1 | 47.24M | $307.27M | +2 | −1 |
| Q4 2024 | 14 | +1 | 50.10M | $405.72M | +1 | — |
| Q3 2024 | 13 | +1 | 47.82M | $391.50M | +2 | −1 |
| Q2 2024 | 12 | — | 55.66M | $388.80M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Icahn Capital ✦ | 34.72M | 0.0% | $283.32M | 2.9% | Held | 2 | SEC ↗ |
| 2 | Citadel Advisors ✦ | 5.14M | -27.3% | $41.98M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 3 | Citadel Advisors ✦ | 5.14M | -27.3% | $41.98M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 4 | Arrowstreet Capital ✦ | 3.26M | -23.1% | $26.61M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 5 | Oaktree Capital Management ✦ | 1.27M | 0.0% | $10.36M | 0.2% | Held | 2 | SEC ↗ |
| 6 | GAMCO Investors ✦ | 1.06M | -9.6% | $8.67M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 7 | Geode Capital Management ✦ (passive) | 636.08K | +20.5% | $6.45M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 8 | Geode Capital Management ✦ (passive) | 636.08K | +20.5% | $6.45M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 9 | Norges Bank ✦ (passive) | 724.49K | -80.8% | $5.91M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 10 | Millennium Management ✦ | 401.81K | -55.3% | $3.28M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 11 | D. E. Shaw & Co. ✦ | 295.84K | -28.4% | $2.41M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 12 | D. E. Shaw & Co. ✦ | 295.84K | -28.4% | $2.41M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 13 | Bridgewater Associates ✦ | 234.82K | -5.2% | $1.92M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 14 | Two Sigma Investments ✦ | 33.68K | New | $274,829 | 0.0% | New | 1 | SEC ↗ |
| 15 | Renaissance Technologies ✦ | 26.60K | New | $217,056 | 0.0% | New | 1 | SEC ↗ |
| 16 | Elliott Investment Management ✦ | 11.50K | 0.0% | $93,843 | 0.0% | Held | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Two Sigma Investments | $274,829 | 0.0% |
| Renaissance Technologies | $217,056 | 0.0% |
Exited
| Glenview Capital | $9.11M | was 0.2% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 224 holders, 232.19M shares, $1.23B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 36.83K sh · $258,894
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology